首页 > 市场调查报告书 > 製药

疼痛

市场调查报告书

商品编码

1361560

医用大麻市场 - 2018-2028F 全球产业规模、份额、趋势、机会和预测，按产品类型、活性成分、配销通路、按应用、最终用户行业、地区和竞争细分

Medical Cannabis Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F Segmented By Product Type, By Active Ingredient, By Distribution Channel, By Application, By End User Industry, By Region and Competition

出版日期: 2023年10月03日 | 出版商:

TechSci Research | 英文 180 Pages | 商品交期: 2-3个工作天内

价格

简介目录

全球医用大麻市场预计复合年增长率为 14.62%，到 2028 年将达到 475.8 亿美元。这归因于政府资金的增加、研发活动 (R&D) 的增加以及世界各地接受度的提高。医用大麻市场是一个快速成长的行业，正在世界许多国家获得接受和法律认可。

医用大麻是指使用大麻植物或其萃取物来治疗一系列疾病，包括慢性疼痛、噁心、癫痫发作和焦虑等。医用大麻市场包括多种产品，包括干燥大麻花、油、胶囊、酊剂和食品。这些产品可以根据患者的需求和偏好以不同的方式给药，例如吸烟、蒸发或摄入。推动医用大麻市场成长的主要因素之一是大众越来越接受大麻作为合法的医疗选择。随着对大麻的医疗特性进行越来越多的研究，并且越来越多的患者报告使用大麻来控制病情的正面效果，对医用大麻产品的需求正在增长。在澳大利亚，医用大麻于2016年合法化，根据治疗产品管理局的调查，医用大麻处方数量从2017年的1,000张增加到2021年的10万张以上。

医用大麻市场，依产品类型：

花蕾/大麻花

大麻萃取物

医用大麻市场（依活性成分）：

四氢大麻酚 (THC)

大麻二酚（CBD）

其他的

医用大麻市场，按配销通路：

企业对企业

企业对消费者

医用大麻市场，按应用：

慢性疼痛

精神错乱

癌症

癫痫

其他的

医用大麻市场，按最终用户划分：

製药与生物技术公司

学术研究机构

其他的

医用大麻市场，按地区：

北美洲

美国
墨西哥
加拿大

欧洲

德国
马尔他
英国
法国
丹麦
义大利
西班牙

亚太

澳洲
中国
泰国
韩国
印度

南美洲

巴西
阿根廷
哥伦比亚

中东和非洲

黎巴嫩
南非
以色列

竞争格局

公司简介：全球医用大麻市场主要公司的详细分析。

可用的客製化：

根据给定的市场资料，TechSci Research 可根据公司的具体需求提供客製化服务。该报告可以使用以下自订选项：

公司资讯

其他市场参与者（最多五个）的详细分析和概况分析。

市场规模及预测
- 按价值
市占率及预测
- 依产品类型（花蕾/大麻花、大麻萃取物）
- 依活性成分（四氢大麻酚（THC）、大麻二酚（CBD）、其他）
- 按配销通路（B2B、B2C）
- 按应用（慢性疼痛、精神障碍、癌症、癫痫等）
- 按最终用户产业（製药和生物技术公司、学术和研究机构、其他）
- 按地区
- 按公司划分 (2022)
产品图
- 依产品类型
- 按活性成分
- 按配销通路
- 按应用
- 按最终用户
- 按地区

第 7 章：北美医用大麻市场展望

市场规模及预测
- 按价值
市占率及预测
- 依产品类型（花蕾/大麻花、大麻萃取物）
- 依活性成分（四氢大麻酚（THC）、大麻二酚（CBD）、其他）
- 按配销通路（B2B、B2C）
- 按应用（慢性疼痛、精神障碍、癌症、癫痫等）
- 按最终用户产业（製药和生物技术公司、学术和研究机构、其他）
- 按国家/地区
北美：国家分析
- 美国
- 加拿大
- 墨西哥

第 8 章：欧洲医用大麻市场展望

市场规模及预测
- 按价值
市占率及预测
- 依产品类型（花蕾/大麻花、大麻萃取物）
- 依活性成分（四氢大麻酚（THC）、大麻二酚（CBD）、其他）
- 按配销通路（B2B、B2C）
- 按应用（慢性疼痛、精神障碍、癌症、癫痫等）
- 按最终用户产业（製药和生物技术公司、学术和研究机构、其他）
- 按国家/地区
欧洲：国家分析
- 德国
- 马尔他
- 英国
- 法国
- 丹麦
- 义大利
- 西班牙

第 9 章：亚太地区医用大麻市场展望

市场规模及预测
- 按价值
市占率及预测
- 依产品类型（花蕾/大麻花、大麻萃取物）
- 依活性成分（四氢大麻酚（THC）、大麻二酚（CBD）、其他）
- 按配销通路（B2B、B2C）
- 按应用（慢性疼痛、精神障碍、癌症、癫痫等）
- 按最终用户产业（製药和生物技术公司、学术和研究机构、其他）
- 按国家/地区
亚太地区：国家分析
- 澳洲
- 中国
- 泰国
- 韩国
- 印度

第 10 章：南美洲医用大麻市场展望

市场规模及预测
- 按价值
市占率及预测
- 依产品类型（花蕾/大麻花、大麻萃取物）
- 依活性成分（四氢大麻酚（THC）、大麻二酚（CBD）、其他）
- 按配销通路（B2B、B2C）
- 按应用（慢性疼痛、精神障碍、癌症、癫痫等）
- 按最终用户产业（製药和生物技术公司、学术和研究机构、其他）
- 按国家/地区
南美洲：国家分析
- 巴西
- 阿根廷
- 哥伦比亚

第 11 章：中东和非洲医用大麻市场展望

市场规模及预测
- 按价值
市占率及预测
- 依产品类型（花蕾/大麻花、大麻萃取物）
- 依活性成分（四氢大麻酚（THC）、大麻二酚（CBD）、其他）
- 按配销通路（B2B、B2C）
- 按应用（慢性疼痛、精神障碍、癌症、癫痫等）
- 按最终用户产业（製药和生物技术公司、学术和研究机构、其他）
- 按国家/地区
MEA：国家分析
- 黎巴嫩医用大麻
- 南非医用大麻
- 以色列医用大麻

第 12 章：市场动态

司机
- 慢性病盛行率高
- 医用大麻合法化
挑战
- 成本高且并不总是容易获得
- 消费者接受度较低

第 13 章：市场趋势与发展

新产品开发
医药行业越来越多地使用医用大麻。

第 14 章：全球医用大麻市场：SWOT 分析

第 15 章：波特的五力分析

产业竞争
新进入者的潜力
供应商的力量
客户的力量
替代产品的威胁

第16章：竞争格局

商业概览
产品供应
最近的发展
财务（据报导）
主要人员
SWOT分析

第17章：战略建议

简介目录

Product Code: 15430

Global medical cannabis market is expected to register a CAGR of 14.62% and reach USD 47.58 billion by 2028. This is attributed to the growing government fundings, increase in research and development activities (R&D), and growing acceptance across the world. The medical cannabis market is a rapidly growing industry that is gaining acceptance and legal recognition in many countries around the world.

Medical cannabis refers to the use of the cannabis plant or its extracts to treat a range of medical conditions, including chronic pain, nausea, seizures, and anxiety, among others. The market for medical cannabis includes a wide range of products, including dried cannabis flower, oils, capsules, tinctures, and edibles. These products can be administered in different ways, such as smoking, vaporizing, or ingestion, depending on the patient's needs and preferences. One of the main factors driving the growth of the medical cannabis market is increasing public acceptance of cannabis as a legitimate medical treatment option. As more research is conducted into the medical properties of cannabis and more patients report positive outcomes from using cannabis to manage their conditions, demand for medical cannabis products is growing. In Australia, medical cannabis was legalized in 2016, and the number of medical cannabis prescriptions has increased from 1,000 in 2017 to over 100,000 in 2021, according to the surveys conducted by Therapeutic Goods Administration.

The medical cannabis market is benefiting from advancements in cannabis cultivation and production techniques, which are leading to higher-quality products and greater consistency in dosing and potency. The legalization of medical cannabis has made it easier for patients to access this treatment option, especially in places where it was previously illegal. A study published in JAMA Internal Medicine found that states with medical cannabis laws had a 25% lower opioid overdose mortality rate compared to states without medical cannabis laws.

Hence, the medical cannabis market is expected to continue to grow as more patients and healthcare professionals recognize the potential benefits of cannabis as a medical treatment option and as more countries legalize medical cannabis use. This advancements and legalization of medical cannabis in different countries is likely to boost the medical cannabis market in the forecast period.

Legalization of Medical Cannabis to drive the Medical Cannabis Market Growth

The medical cannabis market has been rapidly growing in recent years due to various factors such as changing public attitudes towards the medical cannabis, patient testimonials, and opioid crisis. The legalization of medical cannabis in many countries and states has led to increased availability and accessibility of cannabis for medical use. This has helped to create a legal framework for the production, distribution, and consumption of medical cannabis products, making it easier for patients to access them. Also, there is growing acceptance and awareness about the potential benefits of medical cannabis in treating a wide range of medical conditions such as chronic pain, anxiety, and epilepsy. This has led to increased demand for medical cannabis products, and more people are willing to try them as a potential alternative to traditional medications. As more research is conducted on the potential health benefits of medical cannabis, more evidence is emerging to support medical cannabis use in the treatment of various medical conditions. This has helped to increase the credibility of medical cannabis as a legitimate treatment option, which in turn has encouraged more patients to consider using it. Therefore, the growing occurrences of chronic diseases across the globe is influencing the growth of the global medical cannabis market in the coming years

Legalization increases the number of patients who can access medical cannabis products. When medical cannabis is illegal, patients may be forced to obtain it from the black market, which can be risky and unsafe. Legalization ensures that patients have access to legal and regulated products, which can help to improve the quality of their healthcare. In addition to improving access and safety, legalization creates economic opportunities in the medical cannabis market. Legalization can create jobs, generate tax revenue, and encourage investment in research and development. This can help to drive innovation in the medical cannabis industry, leading to the development of new and more effective products. Countries that legalize medical cannabis can benefit from the economic and public health potential, and manage the legal and social implications. In 2018, the World Health Organization Expert Committee on Drug Dependence, conducted a review of cannabis and its derivatives, including cannabidiol (CBD) and tetrahydrocannabinol (THC), and recommended that cannabis and certain cannabis-related substances should be rescheduled under international drug control conventions to facilitate research into their potential therapeutic uses. Also, WHO stated that CBD has been shown to be effective in treating some forms of epilepsy and tetrahydrocannabinol (THC) may have therapeutic benefits for certain medical conditions such as chronic pain, nausea, and vomiting.

Growing Acceptance and Awareness About the Potential Benefits Drive the Market

Growing acceptance and awareness about the potential benefits of medical cannabis is leading to an increase in demand for medical cannabis in the market. Cannabis contains compounds called cannabinoids, which have been found to have various therapeutic properties for example, cannabinoids can help alleviate symptoms of chronic pain, nausea and vomiting, anxiety, and sleep disorders. In response, more countries and states are legalizing medical cannabis, which further drives the demand. Additionally, advancements in technology have made it easier to extract and produce cannabis-based products, making them more accessible to patients who need them. Therefore, the growing acceptance and awareness of medical cannabis are driving the demand for medical cannabis in the market.

Also, more countries and states legalize medical cannabis, more patients have access to medical cannabis. This has led to a significant increase in demand as patients seek alternative therapies to traditional medicines. Cannabis-based products are being marketed more effectively, with companies emphasizing their therapeutic properties and safety. This has led to increased consumer awareness and demand. The perception of cannabis has shifted in recent years, with more people accepting cannabis potential medical benefits. This has led to greater demand from patients who may have previously been reluctant to try medical cannabis. Therefore, the growing acceptance of people towards the use of medical cannabis is likely to fuel the medical cannabis market in the forecast period.

Medical cannabis has been found to have several potential benefits in treating various medical conditions such as Medical cannabis has shown to be effective in reducing chronic pain, including neuropathic pain, back pain, and arthritis. Cannabis-based products can be effective in reducing nausea and vomiting caused by chemotherapy, HIV/AIDS medications, and other medical treatments. Cannabinoids found in medical cannabis have been shown to reduce symptoms of anxiety and depression. As Per The Data Quoted By The National Conference Of State Legislatures, As of April 24, 2023, the District of Columbia, three territories, and 38 states permit the use of cannabis products for medical purposes.

Hence, the growing acceptance and awareness of medical cannabis has created a significant increase in demand for medical cannabis in the market, with patients seeking alternative therapies for a range of medical conditions.

Favorable Government initiatives and Policies Drive the Medical Cannabis Market Growth

Favorable government initiatives and policies drives the growth of the medical cannabis market as more and more countries and states legalize medical cannabis, there is a growing demand for products that contain cannabis and its derivatives. Government initiatives that support research and development of medical cannabis, provide funding for medical cannabis businesses, and streamline the regulatory process that contribute to the growth of the medical cannabis market.

In addition, government policies that allow for easier access to medical cannabis for patients and healthcare professionals, such as removing barriers to prescribing and dispensing, can help to drive the growth. This can lead to increased adoption of medical cannabis as a treatment option, which in turn can drive demand for related products and services. However, different countries and states have different policies and regulations regarding medical cannabis. Some may have strict requirements for licensing, testing, and quality control, while others may have more relaxed regulations. Therefore, the growth of the medical cannabis market can vary depending on the specific regulatory environment in a given region. According to the data quoted by Savills plc, the majority of the world's legal medicinal cannabis is produced in the UK. The UK output of cannabis-derived pharmaceuticals surged by nearly 500% between 2015 and 2017, reaching 235 tonnes, making it the largest global producer by a significant margin.

Market Segmentation

Global medical cannabis market is segmented based on product type, active ingredient, distribution channel, application, end user, and region. Based on product type, the medical cannabis market is segmented into buds/marijuana flower and cannabis extracts. Based on active ingredient, the medical cannabis market is segmented into Tetrahydrocannabinol (THC), Cannabidiol (CBD), and others. Based on distribution channel, the medical cannabis market is segmented into B2B and B2C. Based on application, the medical cannabis market is divided into chronic pain, mental disorders, cancer, epilepsy, and others. Based on end user, the medical cannabis market is segmented into pharmaceutical & biotechnology companies, academic & research institutions, and others. Based on region, the medical cannabis market is divided into North America, Europe, Asia Pacific, South America, Middle East & Africa.

Company Profiles

Canopy Growth Corporation., Aphria, Inc., Maricann Group, Inc., Tikun Olam - Cannabit Pharmaceuticals Ltd., MedReleaf. Corp., GW Pharmaceuticals plc., Cannabis Sativa, Inc., Medical Marijuana, Inc., Aurora Marijuana Inc., and Cronos Group Inc are some of the key players of global medical Cannabis market.

Report Scope:

In this report, global Medical Cannabis market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:

Medical Cannabis Market, By Product Type:

Buds/Marijuana Flower

Cannabis Extracts

Medical Cannabis Market, By Active Ingredient:

Tetrahydrocannabinol (THC)

Cannabidiol (CBD)

Others

Medical Cannabis Market, By Distribution Channel:

B2B

B2C

Medical Cannabis Market, By Application:

Chronic Pain

Mental Disorders

Cancer

Epilepsy

Others

Medical Cannabis Market, By End User:

Pharmaceutical & Biotechnology Companies

Academic & Research Institutions

Others

Medical Cannabis Market, By Region:

North America

United States
Mexico
Canada

Europe

Germany
Malta
United Kingdom
France
Denmark
Italy
Spain

Asia-Pacific

Australia
China
Thailand
South Korea
India

South America

Brazil
Argentina
Colombia

Middle East & Africa

Lebanon
South Africa
Israel

Competitive landscape

Company Profiles: Detailed analysis of the major companies present in the global Medical Cannabis market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validations
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Clinical Trial Analysis

5.1. Ongoing Clinical Trials
5.2. Completed Clinical Trials
5.3. Terminated Clinical Trials
5.4. Breakdown of Pipeline, By Development Phase
5.5. Breakdown of Pipeline, By Status
5.6. Breakdown of Pipeline, By Study Type
5.7. Breakdown of Pipeline, By Region
5.8. Clinical Trials Heat Map

6. Global Medical Cannabis Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Product Type (Buds/Marijuana Flower, Cannabis Extracts)
- 6.2.2. By Active Ingredient (Tetrahydrocannabinol (THC), Cannabidiol (CBD), Others)
- 6.2.3. By Distribution Channel (B2B, B2C)
- 6.2.4. By Application (Chronic Pain, Mental Disorders, Cancer, Epilepsy, Others)
- 6.2.5. By End User Industry (Pharmaceutical & Biotechnology Companies, Academic & Research Institutions, Others)
- 6.2.6. By Region
- 6.2.7. By Company (2022)
6.3. Product Map
- 6.3.1 By Product Type
- 6.3.2 By Active Ingredient
- 6.3.3 By Distribution Channel
- 6.3.4 By Application
- 6.3.5 By End User
- 6.3.4 By Region

7. North America Medical Cannabis Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Product Type (Buds/Marijuana Flower, Cannabis Extracts)
- 7.2.2. By Active Ingredient (Tetrahydrocannabinol (THC), Cannabidiol (CBD), Others)
- 7.2.3. By Distribution Channel (B2B, B2C)
- 7.2.4. By Application (Chronic Pain, Mental Disorders, Cancer, Epilepsy, Others)
- 7.2.5. By End User Industry (Pharmaceutical & Biotechnology Companies, Academic & Research Institutions, Others)
- 7.2.6. By Country
7.3. North America: Country Analysis
- 7.3.1. United States Medical Cannabis Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Product Type
    - 7.3.1.2.2. By Active Ingredient
    - 7.3.1.2.3. By Distribution Channel
    - 7.3.1.2.4. By Application
    - 7.3.1.2.5. By End User Industry
- 7.3.2. Canada Medical Cannabis Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Product Type
    - 7.3.2.2.2. By Active Ingredient
    - 7.3.2.2.3. By Distribution Channel
    - 7.3.2.2.4. By Application
    - 7.3.2.2.5. By End User Industry
- 7.3.3. Mexico Medical Cannabis Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Product Type
    - 7.3.3.2.2. By Active Ingredient
    - 7.3.3.2.3. By Distribution Channel
    - 7.3.3.2.4. By Application
    - 7.3.3.2.5. By End User Industry

8. Europe Medical Cannabis Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Product Type (Buds/Marijuana Flower, Cannabis Extracts)
- 8.2.2. By Active Ingredient (Tetrahydrocannabinol (THC), Cannabidiol (CBD), Others)
- 8.2.3. By Distribution Channel (B2B, B2C)
- 8.2.4. By Application (Chronic Pain, Mental Disorders, Cancer, Epilepsy, Others)
- 8.2.5. By End User Industry (Pharmaceutical & Biotechnology Companies, Academic & Research Institutions, Others)
- 8.2.6. By Country
8.3. Europe: Country Analysis
- 8.3.1. Germany Medical Cannabis Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Product Type
    - 8.3.1.2.2. By Active Ingredient
    - 8.3.1.2.3. By Distribution Channel
    - 8.3.1.2.4. By Application
    - 8.3.1.2.5. By End User Industry
- 8.3.2. Malta Medical Cannabis Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Product Type
    - 8.3.2.2.2. By Active Ingredient
    - 8.3.2.2.3. By Distribution Channel
    - 8.3.2.2.4. By Application
    - 8.3.2.2.5. By End User Industry
- 8.3.3. United Kingdom Medical Cannabis Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecasty
    - 8.3.3.2.1. By Product Type
    - 8.3.3.2.2. By Active Ingredient
    - 8.3.3.2.3. By Distribution Channel
    - 8.3.3.2.4. B y Application
    - 8.3.3.2.5. By End User Industry
- 8.3.4. France Medical Cannabis Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Product Type
    - 8.3.4.2.2. By Active Ingredient
    - 8.3.4.2.3. By Distribution Channel
    - 8.3.4.2.4. By Application
    - 8.3.4.2.5. By End User Industry
- 8.3.5. Denmark Medical Cannabis Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Product Type
    - 8.3.5.2.2. By Active Ingredient
    - 8.3.5.2.3. By Distribution Channel
    - 8.3.5.2.4. By Application
    - 8.3.5.2.5. By End User Industry
- 8.3.6. Italy Medical Cannabis Market Outlook
  - 8.3.6.1. Market Size & Forecast
    - 8.3.6.1.1. By Value
  - 8.3.6.2. Market Share & Forecast
    - 8.3.6.2.1. By Product Type
    - 8.3.6.2.2. By Active Ingredient
    - 8.3.6.2.3. By Distribution Channel
    - 8.3.6.2.4. By Application
    - 8.3.6.2.5. By End User Industry
- 8.3.7. Spain Medical Cannabis Market Outlook
  - 8.3.7.1. Market Size & Forecast
    - 8.3.7.1.1. By Value
  - 8.3.7.2. Market Share & Forecast
    - 8.3.7.2.1. By Product Type
    - 8.3.7.2.2. By Active Ingredient
    - 8.3.7.2.3. By Distribution Channel
    - 8.3.7.2.4. By Application
    - 8.3.7.2.5. By End User Industry

9. Asia-Pacific Medical Cannabis Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Product Type (Buds/Marijuana Flower, Cannabis Extracts)
- 9.2.2. By Active Ingredient (Tetrahydrocannabinol (THC), Cannabidiol (CBD), Others)
- 9.2.3. By Distribution Channel (B2B, B2C)
- 9.2.4. By Application (Chronic Pain, Mental Disorders, Cancer, Epilepsy, Others)
- 9.2.5. By End User Industry (Pharmaceutical & Biotechnology Companies, Academic & Research Institutions, Others)
- 9.2.6. By Country
9.3. Asia-Pacific: Country Analysis
- 9.3.1. Australia Medical Cannabis Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Product Type
    - 9.3.1.2.2. By Active Ingredient
    - 9.3.1.2.3. By Distribution Channel
    - 9.3.1.2.4. By Application
    - 9.3.1.2.5. By End User Industry
- 9.3.2. China Medical Cannabis Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Product Type
    - 9.3.2.2.2. By Active Ingredient
    - 9.3.2.2.3. By Distribution Channel
    - 9.3.2.2.4. By Application
    - 9.3.2.2.5. By End User Industry
- 9.3.3. Thailand Medical Cannabis Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Product Type
    - 9.3.3.2.2. By Active Ingredient
    - 9.3.3.2.3. By Distribution Channel
    - 9.3.3.2.4. By Application
    - 9.3.3.2.5. By End User Industry
- 9.3.4. South Korea Medical Cannabis Market Outlook
  - 9.3.4.1. Market Size & Forecast
    - 9.3.4.1.1. By Value
  - 9.3.4.2. Market Share & Forecast
    - 9.3.4.2.1. By Product Type
    - 9.3.4.2.2. By Active Ingredient
    - 9.3.4.2.3. By Distribution Channel
    - 9.3.4.2.4. By Application
    - 9.3.4.2.5. By End User Industry
- 9.3.5. India Medical Cannabis Market Outlook
  - 9.3.5.1. Market Size & Forecast
    - 9.3.5.1.1. By Value
  - 9.3.5.2. Market Share & Forecast
    - 9.3.5.2.1. By Product Type
    - 9.3.5.2.2. By Active Ingredient
    - 9.3.5.2.3. By Distribution Channel
    - 9.3.5.2.4. By Application
    - 9.3.5.2.5. By End User Industry

10. South America Medical Cannabis Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Product Type (Buds/Marijuana Flower, Cannabis Extracts)
- 10.2.2. By Active Ingredient (Tetrahydrocannabinol (THC), Cannabidiol (CBD), Others)
- 10.2.3. By Distribution Channel (B2B, B2C)
- 10.2.4. By Application (Chronic Pain, Mental Disorders, Cancer, Epilepsy, Others)
- 10.2.5. By End User Industry (Pharmaceutical & Biotechnology Companies, Academic & Research Institutions, Others)
- 10.2.6. By Country
10.3. South America: Country Analysis
- 10.3.1. Brazil Medical Cannabis Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Product Type
    - 10.3.1.2.2. By Active Ingredient
    - 10.3.1.2.3. By Distribution Channel
    - 10.3.1.2.4. By Application
    - 10.3.1.2.5. By End User Industry
- 10.3.2. Argentina Medical Cannabis Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Product Type
    - 10.3.2.2.2. By Active Ingredient
    - 10.3.2.2.3. By Distribution Channel
    - 10.3.2.2.4. By Application
    - 10.3.2.2.5. By End User Industry
- 10.3.3. Colombia Medical Cannabis Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Product Type
    - 10.3.3.2.2. By Active Ingredient
    - 10.3.3.2.3. By Distribution Channel
    - 10.3.3.2.4. By Application
    - 10.3.3.2.5. By End User Industry

11. Middle East and Africa Medical Cannabis Market Outlook

11.1. Market Size & Forecast
- 11.1.1. By Value
11.2. Market Share & Forecast
- 11.2.1. By Product Type (Buds/Marijuana Flower, Cannabis Extracts)
- 11.2.2. By Active Ingredient (Tetrahydrocannabinol (THC), Cannabidiol (CBD), Others)
- 11.2.3. By Distribution Channel (B2B, B2C)
- 11.2.4. By Application (Chronic Pain, Mental Disorders, Cancer, Epilepsy, Others)
- 11.2.5. By End User Industry (Pharmaceutical & Biotechnology Companies, Academic & Research Institutions, Others)
- 11.2.6. By Country
11.3. MEA: Country Analysis
- 11.3.1. Lebanon Medical Cannabis Market Outlook
  - 11.3.1.1. Market Size & Forecast
    - 11.3.1.1.1. By Value
  - 11.3.1.2. Market Share & Forecast
    - 11.3.1.2.1. By Product Type
    - 11.3.1.2.2. By Active Ingredient
    - 11.3.1.2.3. By Distribution Channel
    - 11.3.1.2.4. By Application
    - 11.3.1.2.5. By End User Industry
- 11.3.2. South Africa Medical Cannabis Market Outlook
  - 11.3.2.1. Market Size & Forecast
    - 11.3.2.1.1. By Value
  - 11.3.2.2. Market Share & Forecast
    - 11.3.2.2.1. By Product Type
    - 11.3.2.2.2. By Active Ingredient
    - 11.3.2.2.3. By Distribution Channel
    - 11.3.2.2.4. By Application
    - 11.3.2.2.5. By End User Industry
- 11.3.3. Israel Medical Cannabis Market Outlook
  - 11.3.3.1. Market Size & Forecast
    - 11.3.3.1.1. By Value
  - 11.3.3.2. Market Share & Forecast
    - 11.3.3.2.1. By Product Type
    - 11.3.3.2.2. By Active Ingredient
    - 11.3.3.2.3. By Distribution Channel
    - 11.3.3.2.4. By Application
    - 11.3.3.2.5. By End User Industry

12. Market Dynamics

12.1. Drivers
- 12.1.1 High prevalence of Chronic
- 12.1.2 Legalization of Medical Cannabis
12.2. Challenges
- 12.2.1 High cost and not always readily available
- 12.2.2 Less acceptance by the Consumer